Navigation Links
Health Care Reform, Sex Education, Disaster Preparedness Among Public Health Issues at APHA Annual Meeting, Oct. 25-29
Date:9/15/2008

Renowned Public Health Leaders to Open and Close Meeting

WASHINGTON, Sept. 15 /PRNewswire-USNewswire/ -- Thousands of public health experts will gather in San Diego, Oct. 25-29, to tackle pressing health concerns facing the nation during the American Public Health Association's (APHA) 136th Annual Meeting & Exposition. Press registration is available at http://www.apha.org/about/news/ampressinfo/.

The 2008 APHA Annual Meeting & Exposition is themed "Public Health Without Borders." Along with thematic topics like refugee health, water and land rights, and pollution management across borders, Annual Meeting sessions will also address pressing issues of political importance, such as health care reform and reproductive rights.

The meeting kicks off Sunday, Oct. 26, with a presentation by Sir Michael Marmot, MBBS, MPH, PhD, FRCP, FFPHM, FMedSci, director of the International Institute for Society and Health. A panel of former surgeons general, Richard H. Carmona, MD, MPH, FACS; David Satcher, MD, PhD; and M. Joycelyn Elders, MD, will speak at the Closing Session on Wednesday, Oct. 29. In between, more than 900 scientific sessions will provide the most up-to-date public health research reflecting the broad impact of the field on our lives.

The APHA Annual Meeting & Exposition is the oldest and largest gathering of public health professionals in the world. All APHA Annual Meeting scientific sessions are listed online and are fully searchable at http://www.apha.org/meetings. To view the program schedule for each session and to see the abstracts for each presentation, please visit http://www.apha.org/meetings/sessions/. Final programs with session locations along with daily news media updates will be available on-site at the APHA Press Office. '/>"/>

SOURCE American Public Health Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Staten Island University Hospital to Pay the U.S. $74 Million to Settle Claims of Defrauding Federal Health Care Programs
2. US must enact measures to support the role of IMGs in US health-care delivery, says ACP
3. Harvard University recipient of Global Health Nutrition grant
4. Girling Health Care Employees and Patients Urged to Call for Instructions
5. McCulley/Cuppan Consultants Contribute Chapter to the Newly Published Book, Rhetoric of Healthcare: Essays Toward a New Disciplinary Inquiry
6. Health and Agriculture Departments Warn Consumers About Raw Milk Sold in Montgomery County
7. USHEALTH Group Launches Marketing Program for Two Health Insurance Plans Targeting Latino Residents in Florida
8. Rally for Health Care for the Uninsured as Legislature Reconvenes for Fall Session
9. WellPoint Adjusts Health and Pharmacy Guidelines for Members in Texas and Louisiana Affected by Hurricane Ike
10. DNC: Bush-McCain Alert - President Touts Bush-McCain Health Care Agenda in Oklahoma
11. Free Health, Dental and Vision Screenings This Sunday Will Help Lancaster County Children and Adults
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Millions Flowing into Medical Real Estate 13292 1Millions Flowing into Medical Real Estate 13292 2Millions Flowing into Medical Real Estate 13292 3Insurance Department Releases Report on Executive Compensation at States Largest Blues Plans 53231 1Insurance Department Releases Report on Executive Compensation at States Largest Blues Plans 53231 2